Cost-effectiveness Analysis Of Concomitant Therapy And Bismuth Quadruple Therapy For Helicobacter Pylori Eradication

Objective:To compare the cost-effectiveness of concomitant therapy and bismuth quadruple therapy for Helicobacter pylori(Hp)eradication.Methods:From December 2015 to December 2016,156 outpatients from the People's Hospital of Xinjiang Uygur Autonomous Region who were positive for 14C-UBT were enrolled.Randomly divided into A ? B group,76 cases in A group,80 cases in B group.Group A with concomitant therapy: rabeprazole 20 mg twice daily,metronidazole 400 mg twice daily,clarithromycin400 mg twice daily,amoxicillin 1000 mg twice daily;Group B with bismuth quadruple therapy: rabeprazole 20 mg twice daily,clarithromycin 400 mg twice daily,amoxicillin1000 mg twice daily,bismuth 150 mg three times a day.The course of treatment sustain 14 days,14C urea breath test was reassessed at four weeks after the cessation of therapy.Then compare the cost-effectiveness of the two therapy.Results:By ITT analysis,the eradication rates of two regimens were 82.9%,86.3%,the difference of eradication rates were not sattisticallly sinificant(P=0.467).The cost of the two group were1082.63 yuan,1114.05 yuan respectively.The cost-effectiveness ratio(C/E)were13.05/12.91.Conclusion: Concomitant therapy and bismuth quadruple therapy is equivalent in economy and effectiveness.They are all worth to recommended as first-line therapy in China.